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The secreted proteins from a cell constitute a natural bio-
logic library that can offer significant insight into human 
health and disease. Discovering new secreted proteins 
from cells is bounded by the limitations of traditional sep-
aration and detection tools to physically fractionate and 
analyze samples. Here, we present a new method to sys-
tematically identify bioactive cell-secreted proteins that 
circumvent traditional proteomic methods by first enrich-
ing for protein candidates by differential gene expression 
profiling. The bone marrow stromal cell secretome was 
analyzed using enriched gene expression datasets in 
combination with potency assay testing. Four proteins 
expressed by stromal cells with previously unknown anti-
inflammatory properties were identified, two of which 
provided a significant survival benefit to mice chal-
lenged with lethal endotoxic shock. Greater than 85% 
of secreted factors were recaptured that were otherwise 
undetected by proteomic methods, and remarkable hit 
rates of 18% in vitro and 9% in vivo were achieved.
Received 15 July 2013; accepted 30 January 2014; advance online  
publication 18 March 2014. doi:10.1038/mt.2014.17
INTRODUCTION
Cells can communicate by secreting proteins that act on neigh-
boring or distant target cells to regulate function and phenotype. 
Identification of these communication signals has led to a deeper 
understanding of physiological processes involved in health and 
disease, including cell proliferation,1 differentiation,2 motility,3 and 
apoptosis.4 Secreted proteins have also become important in the 
development of some of the most successful therapies in history. 
These therapies are generally designed to either increase the natu-
ral levels by administration of recombinant proteins or decreas-
ing the level by use of neutralizing agents, such as antibodies. 
Insulin, a secreted pancreatic hormone, has been supplemented 
for decades as a first-line therapy for regulating the uptake of glu-
cose by target cells in diabetic patients (2011 US sales: $9.8B).5,6 
Interferon-α and interferon-β are widely used to treat hepatitis C 
virus infection and multiple sclerosis, respectively (collective 2011 
US sales: $2.5B).6,7 Proinflammatory cytokines, such as tumor 
necrosis factor (TNF)-α, have become mega-blockbuster phar-
maceutical targets for patients with autoimmune diseases (2011 
US sales of TNF-α inhibitors: $6.8B).6,8 Total US sales in 2011 of 
protein drugs based on native secreted proteins exceeded $32B.6
Identification of secreted proteins has primarily relied on 
hypothesis-driven interrogation and is limited to known biologi-
cal pathways.9 Open-ended screening approaches that assume 
less about the underlying biology are impractical because estab-
lishment of libraries of all known secreted proteins is cost- 
prohibitive; probing the vast interactome is intractable; and not 
all proteins synthesized in the human body can be made recom-
binantly.10 A bottom-up approach to access and dissect a finite 
library of secreted proteins involves the analysis of conditioned 
medium (CM) from a cell. Traditional biochemical methods for 
characterizing CM, such as liquid chromatography (LC) and mass 
spectrometry (MS), have led to the discovery of many important 
proteins including interferon and hepatocyte growth factor.11,12 
These methods are, however, labor intensive because of the need 
to grow billions of cells in order to generate liters of CM and elimi-
nate serum and albumin contaminants for sensitive analysis.13,14 
These challenges have restricted discovery efforts in academic and 
industrial laboratories. New methods to elucidate secreted pro-
teins and the pathways they influence can accelerate the discovery 
of new signaling molecules for biological research and therapeutic 
testing.
A new, simple method for discovering potential secreted 
protein communication pathways is reported here. The method 
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(referred to as enriched protein screening (EPS)) circumvents the 
need for LC/MS by using comparative gene profiling to enrich for 
active secreted proteins that can be recombinantly screened in 
bioassays (Figure 1). A human peripheral blood mononuclear cell 
(PBMC) inflammation assay was used to screen candidates natu-
rally expressed by human bone marrow mesenchymal stromal cells 
(BM-MSCs)15 as a proof of concept. BM-MSCs are stem-like cells 
that are being explored clinically as a therapeutic for a variety of 
inflammatory and autoimmune diseases.16 The implementation of 
EPS led to the discovery of two novel immunomodulatory proteins, 
microfibrillar-associated protein 5 (MFAP5) and unprocessed pro-
enkephalin (PENK), that when administered to mice subjected to 
endotoxemic shock, reversed the cytokine storm and provided a 
significant survival benefit comparable to the gold-standard anti-
inflammatory biologic, monoclonal anti-TNF-α antibodies.
RESULTS
Development of a human blood potency assay to 
analyze BM-MSC–secreted factors
BM-MSCs have been extensively reported to have anti-inflam-
matory properties when used in a transplantation setting.17 
Interleukin (IL)-10 is increased in the serum of inflamed rodents 
after treatment with BM-MSCs or a bolus of concentrated 
BM-MSC-CM.18 A potency assay was developed to recapitulate 
this IL-10 response in vitro using primary human PBMCs to 
evaluate the bulk anti-inflammatory activity of BM-MSC-CM 
(Figure 2a). PBMCs were incubated with BM-MSC-CM and then 
stimulated with lipopolysaccharide (LPS) to instigate a proinflam-
matory response. LPS-stimulated production of IL-10 by human 
PBMCs increased significantly when the cells were preincubated 
with BM-MSC-CM (Figure 2b; Supplementary Figure S2a). 
Upregulation of IL-10 release was dose dependent (Figure 2c), 
suggesting that the receptors responsible for IL-10 release were 
not saturated in this range of CM. Digestion of BM-MSC-CM 
with proteinase K attenuated the IL-10 response, confirming the 
causative role of proteins in the CM (Supplementary Figure S2b). 
BM-MSC-CM also suppressed inflammatory interferon (IFN)-γ 
production in this assay (Supplementary Figure S3). Boosting of 
IL-10 was further used as an assay endpoint because it is less prone 
to nonspecific assay artifacts, such as suppressed IFN-γ expression 
from cytotoxicity. The sensitivity of the PBMC assay was tested 
using fractions of BM-MSC-CM based on size (Supplementary 
Figure S4a) and charge (Supplementary Figure S4b), and clear 
delineation of active regions confirmed sufficient detection sen-
sitivity of the assay.
Genomic enrichment of BM-MSC–secreted proteins 
based on potency
A comparative gene expression scheme was developed to rationally 
enrich candidate proteins that contribute to the anti-inflammatory 
Figure 1 Enriched protein screening (EPS). A generalized schematic of EPS methodology. Protein products are derived from various cell types in 
the form of conditioned media and screened for activity in an in vitro potency assay. Based on the activity of the conditioned media from the cells, 
differential gene expression profiling is performed to select for genes uniquely upregulated in the cell type with the highest activity in the potency 
assay. Recombinant protein products of the enriched gene list are then screened in the same potency assay and candidates with the highest activity 
are assessed for activity in vivo.
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Figure 2 In vitro blood inflammation assay. (a) An IL-10 in vitro potency assay for this study. This assay entails incubating primary human PBMCs in 
the presence of protein products (e.g., conditioned medium from a cell) for 16 hours, followed by stimulation of the PBMCs with (LPS) for 5 hours, 
and measurement of IL-10 secretion into the supernatant via ELISA. (b) Time course of IL-10 expression from PBMCs when incubated with either bone 
marrow stromal cell conditioned medium (BM-MSC-CM) or unconditioned medium (DMEM) in the potency assay. (c) Dose response of the potency 
assay to increasing concentration of BM-MSC-CM. 15× CM was either diluted or concentrated further to generate the different concentrations. N 
= 3 independent trials. *P < 0.001 compared to DMEM. BM-MSC, bone marrow mesenchymal stromal cell; CM: conditioned medium; DMEM, 
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activity of BM-MSC-CM. Genome-wide datasets were established 
based on the differential potency of CM from three different 
cell populations in boosting IL-10. BM-MSCs were compared 
to human skin fibroblasts (FBs), as FBs express many similar 
genes as BM-MSCs but lacked activity in the PBMC potency 
assay (Figure 3a). Comparison of gene expression of BM-MSCs 
and FBs, yielded a list of ~500 genes uniquely upregulated in 
BM-MSCs. Many of the genes that were upregulated in BM-MSCs 
clustered around an undifferentiated progenitor phenotype and 
were associated with developmental processes (Figure 3b). The 
second largest enriched cluster was secreted glycoproteins.
An additional genomic dataset from a third cell population 
was introduced to further refine gene enrichment. This third 
cell population was an activated BM-MSC to induce a state of 
heightened potency. BM-MSCs display a number of surface cyto-
kine and toll-like receptors that have been implicated in their 
immunomodulatory phenotype.19 BM-MSCs were prestimu-
lated with a selection of proinflammatory ligands prior to con-
ditioning. LPS prestimulation was found to increase the potency 
of BM-MSC-CM significantly (Figure 3c,d). Cluster analysis of 
the BM-MSCLPS≥BM-MSC gene set revealed that many of the 
upregulated genes were associated with an immune response. The 
next largest cluster in this gene set was secreted glycoproteins, 
which were preferentially enriched after LPS stimulation (Figure 
3e). These data further supported the hypothesis that a contrast 
hierarchy of BM-MSCLPS≥BM-MSC>FB would accentuate key 
secreted molecules responsible for the IL-10 phenomenon. This 
contrast hierarchy revealed 139 genes (Figure 3f). A literature 
search to determine which of these genes correspond to a secreted 
protein yielded a highly enriched set of 22 genes (Figure 3g).
Recombinant protein library construction and 
screening
The gene expression hierarchy revealed a highly enriched set of 
22 genes that hypothetically encode the secreted proteins that 
contribute to the IL-10 boosting capacity of BM-MSC-CM. This 
hypothesis was tested by assembling a purified recombinant 
protein library based on the 22 candidate genes and screen-
ing the proteins in the inflammation assay. The screen was 
performed using a range of physiologically relevant concentra-
tions and 4 of the 22 screened proteins successfully upregulated 
IL-10 secretion when present at ~100 nmol/l concentrations, 
Figure 3 Gene contrast hierarchy and generation of screening library. (a) Comparison of potency assay activity of conditioned medium from 
FB-CM and BM-MSC-CM. *P < 0.001 compared to FB-CM. N = 3 independent trials. (b) The top five ontological gene clusters for the contrast 
set of BM-MSC>FB. N = 3 independent microarrays per group. (c) Effect of preconditioning BM-MSCs with stimulatory ligands on the activity of 
BM-MSC-CM in the potency assay. N = 2 independent trials. (d) Comparison of potency assay activity of conditioned medium from BM-MSC-CM 
and BM-MSCs preincubated with LPS prior to conditioning (BM-MSCLPS-CM). *P < 0.001 compared to BM-MSC-CM. N = 3 independent trials. (e) 
Top five ontological gene clusters for the contrast set of BM-MSCLPSBM-MSC. N = 3 independent microarrays per group. (f) Schematic of the gene 
expression comparison scheme. Genes correlating with anti-inflammatory activity were selected by taking the intersection of the sets of all genes 
upregulated in BM-MSCs compared to FBs and all genes expressed equally or upregulated in BM-MSCLPS compared to BM-MSCs. (g) Gene expression 
profiling revealed 22 genes responsible for secreted proteins that were upregulated by BM-MSCs stimulated with LPS compared to BM-MSCs and FBs. 
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polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1), 
galectin-3-binding protein (LGALS3BP), MFAP5, and PENK 
(Figure 4). Semiquantitative western blots were performed 
for GALNT1, MFAP5, and PENK, and a quantitative enzyme-
linked immunosorbent assay (ELISA) was used for LGALS3BP 
(Figure 5a) to test whether these proteins were present in the 
BM-MSC-CM. Clear bands were observed for MFAP5 and ELISA 
results showed LGALS3BP to be present at ng/ml concentrations 
in the BM-MSC-CM. GALNT1 and PENK were not present at 
detectable levels, even when the CM was concentrated 100-fold. 
Proteomic LC/MS was also performed on bulk BM-MSC-CM and 
several of the 22 proteins in the enriched library were identified, 
including LGALS3BP (Figure 5b). Nevertheless, LC/MS failed to 
discern 19 of the 22 library proteins (86%) as uniquely expressed 
by BM-MSCs, including all hits from the PBMC assay screen. 
Interestingly, no molecules previously reported to be important 
for BM-MSC therapy were discovered during the EPS analysis. A 
retrospective gene expression survey revealed that the design of 
the contrast hierarchy excluded all proteins previously reported 
to be therapeutic (Figure 5c). Certain genes were preferentially 
upregulated in one of the direct contrast sets but not both, includ-
ing TGF-β2 in the BM-MSC>FB set and COX-2, IDO, IL-1RAG, 
IL-6, and TSG-6 in the BM-MSCLPS≥BM-MSC set (LogFC>1.5; 
P < 0.01). Taken together, these results demonstrate an unprec-
edented in vitro hit rate of novel protein discovery via EPS (18%), 
which is several orders of magnitude higher than traditional high 
throughput approaches for new chemical entities that achieve in 
vitro rates on the order of 0.03–0.2%.20,21
In vivo validation of protein candidates
The four hits from the enriched recombinant protein screen 
were tested for activity in vivo in animals challenged with a sub-
lethal dose of LPS. Significantly elevated serum IL-10 levels were 
observed in LPS-treated mice receiving BM-MSC-CM, GALNT1, 
MFAP5, and PENK compared to baseline vehicle control (saline), 
but no IL-10 response from LGALS3BP (Figure 6a). Serum TNF-α 
was also significantly suppressed in mice receiving BM-MSC-CM, 
LGALS3BP, MFAP5, and PENK, but not GALNT1 (Figure 6a). In 
addition, MFAP5 and PENK demonstrated superior TNF-α sup-
pression compared to BM-MSC-CM.
The effects of cytokine modulation were apparent in the lung 
histology of the animals (Figure 6b). In vehicle treated animals, 
inflammatory infiltrate and alveolar collapse were evident in all lung 
fields confirming acute lung injury and respiratory distress in this 
model. LGALS3BP, PENK, and MFAP5 showed increased alveo-
lar space in the majority of the lungs, with slight decreased space 
in BMSC-CM- and GALNT1-treated mice. PENK, MFAP-5, and 
BM-MSC-CM showed reductions in apparent inflammatory infil-
trate, while GALNT1 and LGALS3BP mice had increased infiltrates. 
Collectively, only MFAP-5 and PENK had both associated lung 
changes of increased alveolar space and reduced infiltration that 
would suggest an overall improvement and protection of LPS injury. 
Figure 4 Screening of the enriched recombinant protein candidates. Enriched recombinant protein screen of 22 candidates using the potency 
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Histological analysis was also performed of liver and kidney as other 
prototypical organs affected by endotoxic shock, but no pathological 
changes were observed in any of the treatment or control arms (data 
not shown). The four proteins were also tested in mice challenged 
with a lethal dose of LPS with survival as an endpoint). Compared to 
anti-TNF-α antibodies, a gold-standard anti-inflammatory drug for 
human use,22 MFAP5 and PENK exhibited similar protection and 
provided a significant survival benefit (Figure 6c).
CD14+ human blood monocytes are the target of 
MFAP-5 and PENK
A target cell tracing study was conducted to better understand the 
underlying mechanism of action of MFAP5 and PENK. MFAP5-
GST and PENK-GST were incubated separately with PBMCs 
prior to staining the cells with antibodies against GST and cell 
surface markers to delineate cell subsets. Flow cytometry revealed 
the CD14+ fraction stained strongly for anti-GST in the presence 
of either of the GST-tagged proteins (Figure 7a). Isolated CD14+ 
cells from whole PBMCs were then tested in our potency assay 
and produced the same level of IL-10 as the whole PBMC frac-
tion when exposed to MFAP5 or PENK (Figure 7b), indicating 
that CD14+ monocytes are critical mediators of the IL-10 boosting 
capability of MFAP5 and PENK.
DISCUSSION
EPS has several advantages over traditional methods for 
secreted protein discovery, making it a powerful new strategy 
for uncovering new pathways. First, EPS does not require LC/
MS facilities but instead leverages genomic technologies that 
have standardized operating protocols and are now widely acces-
sible to the biomedical research community. EPS was designed to 
integrate these genomic tools in a modular manner, so that new 
advances in tool development (e.g., RNA sequencing) can also be 
adapted to improve EPS methods for the next generation. Second, 
EPS was capable of superior protein candidate detection com-
pared to traditional LC/MS approaches that failed to reveal 86% 
of the proteins in the EPS-generated screening library. Third, the 
enrichment of candidates by EPS led to an in vitro hit rate of 18% 
and in vivo hit rate of 9% from a tractable library of 22 recom-
binant proteins. These hit rates are several orders of magnitude 
higher than traditional high throughput screening approaches for 
new chemical entities that range from 0.03 to 0.2%.20,21 Finally, by 
using a phenomenological output (i.e., IL-10 upregulation), this 
approach enabled screening without any hypotheses as to the 
nature or existence of receptor targets, thereby bypassing years 
of research required to uncover intermediate ligand–receptor 
interactions.
It is important to discuss the known biology of the top hits 
from the screen, PENK and MFAP5, as neither was previously 
known to possess anti-inflammatory activity. The PENK gene 
encodes a precursor protein that is enzymatically cleaved into 
proenkephalin-A-derived peptides.23 Proenkephalin-A-derived 
peptides have been shown to promote lymphocyte chemotaxis,24 
suppress T-cell activation when secreted by colon cancer cells,25 
Figure 5 Assessment of BM-MSC secretion of the candidate proteins and gene expression evaluation of known therapeutic molecules pro-
duced by BM-MSCs. (a) ELISA and western blotting of FB-CM, BM-MSC-CM, and BM-MSCLPS-CM for LGALS3BP, MFAP5, GALNT1, and PENK. *P 
< 0.001 compared to FB-CM. (b) Partial list of proteins contained in 150× FB-CM, BM-MSC-CM, and BM-MSCLPS-CM detected by proteomic mass 
spectrometry. (c) Contrast gene expression data for known therapeutic molecules expressed by BM-MSCs. N = 2 independent batches of BM-MSCs. 
BM-MSC, bone marrow mesenchymal stromal cell; FB, normal human dermal fibroblasts; GALNT1, polypeptide N-acetylgalactosaminyltransferase 1; 
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201105_at Gal-1 -0.270354715 0.47143256 0.053125775 0.916679526
209960_at HGF 1.618898494 0.061692046 0.524132033 0.598620893
211530_x_at HLA-G -0.413700228 0.055005393 0.862773913 0.002078641
210029_at IDO -0.081592777 0.71585143 1.97802569 0.009814786
207433_at IL-10 -0.107545139 0.576957519 0.039924452 0.768364214
212657_s_at IL-1RAG 0.750861416 0.018317904 3.088452263 0.000531992
205207_at IL-6 -0.384111988 0.10494784 2.256458428 2.58E-06
210037_s_at iNOS -0.108988118 0.563958164 0.095508242 0.525018065
210367_s_at PTGES 1.737782547 0.015361344 0.733193649 0.216248789
223122_s_at SFRP2 0.112434171 0.577381131 -0.119806527 0.486219263
207643_s_at sTNFR1 -0.233496022 0.120481789 0.319819113 0.075144505
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209909_s_at TGF- β2 2.537838331 0.001351263 -0.775070072 0.160136855
209747_at TGF- β3 0.085156434 0.774108851 -0.607040448 0.078505668
206025_s_at TSG-6 0.506390756 0.084731354 2.299118722 0.001177587
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possess antibacterial properties,26 and, depending on the concen-
tration, induce or suppress blastogenesis of human lymphocytes.27 
Although the downstream peptide products of PENK are respon-
sible for observed immunomodulation, the results presented 
herein have discovered that the proprotein has independent 
immunoactivity.24 MFAP5 is an ECM glycoprotein localized to 
microfibrils and associated with elastin networks. MFAP5 binds 
fibrillin-1 and fibrillin-2 at the C-terminus, as well as to other 
proteins containing EGF-like repeats.28 Intracellular MFAP5 has 
been shown to interact with Notch and influence signaling, but 
this phenomenon has not been shown to occur with extracellular 
MFAP5.29 Evidence of its relationship with the immune system is 
limited—to-date, there have been no accounts of MFAP5 influ-
encing immune processes, and its connection to human inflam-
matory disease has not been established. It is interesting to note 
that the MFAP5 gene is located in the natural killer gene complex, 
and this location is conserved across species (observed by the 
authors). Perhaps, the strongest evidence that MFAP5 might play 
an endogenous role in immune function is seen by its relation-
ship to cancer. It has been shown that serum MFAP5 (also known 
as MAGP-2) levels correlate with poor prognosis in patients with 
ovarian cancer.30 In the same study, it was shown that tumor cells 
constitutively express MFAP5 in vitro and could be the source of 
MFAP5 secretion in vivo.30 BM-MSCs are known to accumulate 
at malignant tumor beds and may be an additional, unidentified 
source of MFAP5.31 It is conceivable, judging by their size and the 
pattern of secretion by BM-MSCs and other cells, that MFAP5 
and derivatives of PENK are bona fide cytokines, and may natu-
rally modulate other immune functions besides inflammation.32 
The EPS approach can also be positioned to uncover new biology, 
both in terms of understanding the endogenous role of PENK and 
MFAP5 by BM-MSCs and the anti-inflammatory activity these 
two proteins might naturally have in vivo.
Interestingly, neither PENK nor MFAP5 have been previously 
reported to be expressed by BM-MSCs nor have they been impli-
cated in the molecular mechanisms of BM-MSC therapy.33 In fact, 
the BM-MSCLPS≥BM-MSC>FB contrast hierarchy used here high-
lighted a unique set of genes distinct from all previous reports of 
molecules critical to BM-MSC therapeutic activity (Figure 5c). 
Future studies will be needed to explore the importance of the 
Figure 7 Identification of cellular targets of MFAP5 and PENK. (a) 
Flow cytometry of CD14+ cells from whole human PBMCs incubated 
with either MFAP5-GST, PENK-GST or no protein and then stained for 
GST. (b) LPS potency assay with PBMCs or enriched human monocytes 
from PBMCs and MFAP5 or PENK. BM-MSC, bone marrow mesenchy-
mal stromal cell; FITC, fluorescein isothiocyanate; LPS, lipopolysaccha-
ride; MFAP5, microfibrillar-associated protein 5; PBMC, peripheral blood 
mononuclear cells; PENK: proenkephalin.











































Figure 6 In vivo hit screen and survival study. Proteins were administered IP at the concentration that elicited the strongest effect in vitro, followed 
by IP administration of LPS in conjunction with a second dose of the proteins 16 hours later. Two days after the combined LPS and second protein 
dose, the mice were sacrificed and assessed for changes in serum cytokines and tissue histology. (a) Serum IL-10 and serum TNF-α levels of BALB/
cJ mice subjected to the in vivo LPS assay. *P < 0.001 IL-10 expression compared to saline. #P < 0.001 TNF-α compared to saline, ##P < 0.05 TNF-α 
compared to BM-MSC-CM. N = 4 mice per group. (b) Representative micrographs of lung tissue from mice subjected to the in vivo LPS assay stained 
with hematoxylin and eosin. A table below quantifies alveolar space and mononuclear cell infiltrate per high per field in H&E sections as a % change 
compared to saline treated mice. A positive % change in alveolar space equates to a more normalized tissue state. A negative % change in mononu-
clear infiltrate would equate to normalization to a healthier tissue state. (c) Survival of mice subjected to a lethal dose of LPS i.p. (350 μg) concurrently 
with i.p. saline vehicle (bold dark blue line, n = 20), 300 μg/kg Anti-TNF-α antibody (thin dark blue line, n = 5), 200 μg/kg PENK (bold light blue line, 
n = 5) or 200 μg/kg MFAP5 (thin light blue line, n = 5). *P < 0.005 compared to vehicle control, **P < 0.001 compared to vehicle control. Scale bar 
= 200 μm. i.p., intraperitoneal; LPS, lipopolysaccharide; MFAP5, microfibrillar-associated protein 5; PENK, proenkephalin; TNF, tumor necrosis factor.
Saline BM-MSC-CM GALNT1
LGALS3BP
% Change in alveolar space % Change in infiltrate (MNCs/HPF)
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proteins reported here in the context of BM-MSC therapy. It is 
reasonable to hypothesize that the proteins that did not show 
IL-10 boosting activity may contribute to other anti-inflam-
matory responses by BM-MSCs, such as suppression of IFN-γ. 
Furthermore, the inability to detect levels of GALNT1 or PENK 
in BM-MSC CM suggests that these genes, while expressed, may 
not give rise to whole secreted proteins by BM-MSCs. PENK, for 
example, may be released as peptide derivatives of the proprotein. 
It is also worth noting that while these studies focused on one 
intersecting set of genes, the contrast hierarchy can be modified 
(e.g., FB>BM-MSC>BM-MSCLPS) to ask different questions about 
stromal cell biology and inflammation.
The results presented here suggest the native human proteins 
MFAP5 and PENK can attenuate inflammation by stimulating 
endogenous secretion of IL-10. IL-10 is a pleiotropic cytokine 
that downregulates Th1 cytokine expression34 and macrophage 
activation35; increases B-cell survival, proliferation, and antibody 
production36; and is the master suppressor cytokine secreted by 
regulatory T cells.37 Deficiency of IL-10 in mice results in sponta-
neous colitis,38 and genetic defects in IL-10 signaling are linked to 
systemic lupus erythematosus,39 Crohn’s disease,40 ulcerative coli-
tis,41 and Behçet’s disease42,43 in humans, suggesting an important 
role for the cytokine in suppressing uncontrolled inflammation 
in healthy individuals. IL-10 has been explored as a therapeutic 
in human autoimmune diseases such as psoriasis,44 rheumatoid 
arthritis,45 and Crohn’s disease.46 IL-10 has a short half-life in vivo, 
however, and trials of the recombinant protein have unfortunately 
failed to meet primary endpoints possibly due to limited exposure 
or adverse side effects when dosed at nonphysiological concentra-
tions.47 Boosting endogenous IL-10 with MFAP5 or PENK could 
overcome the limitations of exogenous IL-10 delivery by stimulat-
ing prolonged secretion of IL-10 while simultaneously allowing 
for natural regulatory feedback to prevent immunosuppression or 
severe side effects.
EPS was designed to be versatile and could be applied to other 
cell types for molecular discovery. The cell(s) and assay(s) can be 
substituted to reveal genes that are of interest to the end user. EPS 
may be used for freshly isolated cells thereby circumventing the 
requirement to grow cells ex vivo for LC/MS, a challenge for ter-
minally differentiated cell types. There is also an opportunity to 
use different complex mixtures such as cytoplasmic or membrane 
fractions that are substituted in the place of a secreted mixture. 
With the use of different cell types, development of additional 
assays, and enrichment of new recombinant libraries, EPS can 
be a powerful discovery platform for natural protein biology and 
medicine.
MATERIALS AND METHODS
Statistics. Unless otherwise noted, all experiments were repeated in qua-
druplicate, and all data were assessed for significance using a paired, two-
tailed Student’s t-test.
Cell culture and CM. Human BM-MSCs were isolated, purified, grown, 
and characterized, and human skin FBs grown as described previously.15 
BM-MSCs were grown with minimum essential media—α modification 
(Sigma, St Louis, MO) supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), 1% antibiotic–antimycotic (Sigma), 
20 mg/l gentamicin (Sigma), and 2.5 μg/l basic human fibroblastic growth 
factor (R&D Systems, Minneapolis, MN). Briefly, MSCs isolated from 
human bone marrow aspirates (Lonza, Walkersville, PA), were plated onto 
T175 flasks at a seeding density of 1,000 cells/cm2. After 10 days of growth, 
the BMSCs were rinsed with phosphate-buffered saline (PBS) twice and 
incubated at 37 °C with Trypsin (Life Technologies, Grand Island, NY) 
for 12 minutes to dislodge the cells from the flask for subsequent passag-
ing. Cells were cryopreserved at a concentration of 1 × 106 cells/ml in mini-
mum essential media—α modification containing 10% fetal bovine serum, 
10% dimethyl sulfoxide (Sigma), and 1% penicillin–streptomycin (Sigma). 
Cells were confirmed for a CD45−, CD146+, CD44+, and CD105+ pheno-
type using flow cytometry (Supplementary Figure S1). Antibodies used 
were: CD45-fluorescein isothiocyanate (FITC), CD44-APC, CD105-PE, 
CD11b-FITC, and CD146-FITC (BD Biosciences, Franklin Lakes, NJ). 
Data were acquired using a FACSCalibur (BD Biosciences).
BM-MSCs were used at passage 2–5, which was equivalent to 
5–20 population doublings from the bank created from a bone marrow 
donation. The CM was also collected and concentrated as described 
previously.15 Harvested CM was stored at 4 degrees for no longer than 2 
weeks before concentration and use. For BM-MSCLPS CM and cells used 
for gene expression analysis, BM-MSCs were grown to >80% confluence 
and rinsed twice with PBS. BM-MSC expansion medium, supplemented 
with 1 μg/ml LPS (Escherichia coli 0111:B4; Sigma), was then added to the 
cells for 24 hours. After this stimulation period, the cells were again rinsed 
with PBS twice and incubated for an additional 24 hours with serum-free 
Dulbecco's modified Eagle medium to produce CM. In the majority of 
experiments, CM was concentrated by 15× using Amicon filtration 
columns (Millipore, Billerica, MA) with a 3kDa cut-off. This was achieved 
when 15 ml of conditioning medium was incubated in the presence of 
2 × 106 cells for 24 hours, collected, and concentrated to a final volume 
of 1 ml. In certain cases, the medium was concentrated to 7.5× or 150×.
Prestimulation of BM-MSCs. BM-MSCs were cultured and expanded until 
>80% confluent. The culture medium was aspirated and the cells rinsed 
twice with PBS. Culture medium was added to the cells supplemented with 
varying concentrations of the following: IFN-γ (0.1 μg/l), TNF-α (0.1 μg/
ml), IL-6 (1 ng/ml), and IL-1β (1 ng/ml) (R&D Systems); Poly I:C DNA 
(10 μg/ml) (Invivogen, San Diego, CA); and LPS (1 μg/ml) (E. coli 0111:B4; 
Sigma). The cells were incubated in the presence of these additives for 24 
hours, followed by aspiration of the supernatant, two washes with PBS, and 
addition of Dulbecco's modified Eagle medium conditioning medium. The 
Dulbecco's modified Eagle medium conditioning medium was incubated 
in the presence of the cells for 24 hours when it was collected and concen-
trated as for BM-MSC-CM.
PBMC potency assay. The assay was performed as before.15 Approval for 
the collection of blood from healthy volunteers was obtained from the 
Institutional Review Board of Massachusetts General Hospital. Human 
PBMCs were isolated using a ficoll gradient (density = 1.077 g/cc; GE 
Healthcare, Uppsala, Sweden). The buffy coat was then washed in media, 
centrifuged at 1,500 rpm, and resuspended for cell counting. PBMCs were 
seeded in 96-well round bottom plate at 50 μl per well (100,000 cells per 
well) and incubated at 37 °C for with BMSC-CM or proteins for 18 hours 
before LPS stimulation. For the majority of the experiments, the potency 
assay was terminated at 5 hours for IL-10 analysis.
Staining for the target cell of MFAP5 and PENK. PBMCs were collected 
and incubated on ice for 30 minutes in RPMI 1640 (Sigma), or in RPMI 
1640 containing 1 U/ml of MFAP5-GST or PENK-GST (Abnova, Taipei, 
Taiwan). The cells were then spun down and washed once with PBS prior 
to being resuspended in RPMI containing 100 μg/ml of FITC-anti-GST 
antibodies (Abcam, Cambridge, MA), and incubated for 30 minutes on 
ice. The cells were then spun down and washed once with PBS prior to fix-
ing with 2% PFA. The fixed cells were then analyzed using flow cytometry 
for FITC-positive cells. Forward- and side scattering of FITC-positive cells 
indicated a population overlapping with the predicted size and granularity 
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of monocytes, and the experiment was repeated as described above with the 
addition of 10 μg/ml of PERCP-anti-CD14 during the anti-GST staining 
step. No other populations of cells stained strongly for MFAP5 or PENK.
Purifying primary human monocytes. PBMCs were isolated from 25 ml of 
freshly isolated whole human blood via ficoll gradient (density = 1.077 g/
cc; GE Healthcare), and then monocytes were negatively selected using 
a selection kit using the manufacturer’s instructions (Pan Monocyte 
Isolation Kit; Miltenyi Biotec, Bergisch Gladbach, Germany). A small 
sample of enriched monocytes was stained as indicated above for CD14 
to determine purity using flow cytometry, and only enrichment of >70% 
was considered acceptable for future experimentation. For experiments 
that compared purified monocytes to PBMCs in the same assay format as 
the PBMC potency assay, 105 PBMCs were used per well, and 104 purified 
monocytes. This proportion of monocytes in the PBMC fraction (10% of 
PBMCs) was based on flow cytometry of CD14+ stained PBMCs.
Gene expression analysis. Gene expression was evaluated using 
Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, 
Santa Clara, CA). Array quality was assessed using the R/Bioconductor 
package.48 All arrays passed visual inspection and no technical outliers 
were identified (n = 3 arrays per cell type). Raw CEL files were processed 
using the robust multiarray average algorithm.49 To identify genes cor-
relating with the observed phenotypic groups, we used limma50 to fit a 
statistical linear model to the data and then tested for differential gene 
expression in the contrasts of interest: FB versus BM-MSC; BM-MSC ver-
sus LPS. Results were adjusted for multiple testing using the Benjamini 
and Hochberg method,51 and significance was determined using a false-
discovery-rate cutoff of less than 1%. All genes identified to be upregulated 
in BM-MSCs compared to FBs and either expressed equally or upregu-
lated in BM-MSCLPS compared to BM-MSCs were then analyzed by lit-
erature review for definitive evidence of production of a secreted protein 
by human cells to generate the list of genes reported here. Independent 
analysis conducted in collaboration with a second computational biology 
facility confirmed these same results with >95% overlap of secreted pro-
teins identified via literature review.
Recombinant protein screen. Recombinant proteins were acquired from 
a commercial vendor (Abnova). Quality control tests were performed on 
each lot of new protein to confirm and normalize potency for each batch. 
The amount of protein needed to induce a twofold increase in IL-10 was 
considered as a unit of drug material and showed an approximate range 
of ± 50% difference in protein mass between batches. The proteins were 
diluted in PBS and added to the PBMC potency assay to achieve a range of 
final concentrations spanning ~1 μg/ml to ~0.01 ng/ml.
ELISAs and western blots. The ELISA kits used were provided by commer-
cial vendors and were used according to the manufacturers’ instructions 
(IL-10 in cell supernatants: BD Biosciences; LGALS3BP: Abnova; IL-10 
and TNF-α from animal serum: R&D Systems). To blot for GALNT1, 
MFAP5 and PENK, FB-CM, BM-MSC-CM, and BM-MSCLPS-CM were 
run out using protein gel electrophoresis (Pierce, Rockford, IL) followed by 
blotting using detection antibodies (Sigma) applied at a dilution of 1:500 
(GALNT1 and MFAP5) or 1:100 (PENK), and corresponding secondary 
antibodies (anti-rabbit for GALNT1 and MFAP5 and anti-goat for PENK) 
conjugated with HRP (Sigma). For the LGALS3BP ELISA and the MFAP5 
blot, 1× conditioned media were used, and for the GALNT1 and PENK 
blots, 1-100× conditioned media were used.
MS. MS was performed at the MS core facility of the Beth Israel Deaconess 
Medical Center at Harvard Medical School as previously described.52 10× 
samples of BM-MSC-CM, FB-CM, and BM-MSCLPS-CM were initially 
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
and bands were excised and trypsin digested for analysis via tandem LC/
MS/MS. The false discovery rate for peptide identifications was ~ 1.5% and 
less than 0.5% for protein identifications.
In vivo mouse assay. All procedures were performed in accordance 
with the animal rights policies of the Massachusetts General Hospital 
Subcommittee on Research Animal Care. For the sublethal LPS model, 
8-week-old female BALB/cJ mice (n ≥ 3) (Jackson Laboratories, Bar 
Harbor, ME) were administered an initial dose of either vehicle or one of 
the experimental therapies IP: 200 μl of saline (vehicle), or 3 μg of protein 
(e.g., GALNT1, LGALS3BP, MFAP5, or PENK) diluted in 200 μl of saline, 
or 1 ml of 15× BM-MSC-CM. Sixteen hours later, the mice received a sec-
ond dose of either vehicle or therapy in conjunction with a dose of 100 μg 
of LPS (E. coli 0111:B4; Sigma) diluted in physiological saline. Fourty-eight 
hours later, the mice were sacrificed and tissue and blood were collected 
for analysis. The serum was tested for the presence of IL-10 and TNF-α 
via ELISA and the lungs, livers, and kidneys of the animals were preserved 
for hematoxylin and eosin staining. For the lethal LPS model, 8-week-old 
female BALB/cJ mice (n ≥ 5) were coadministered a lethal dose of LPS (350 
μg LPS in 100 μl physiological saline) and either vehicle (negative control), 
5 μg anti-TNF-α (positive control; R&D Systems), 4 μg MFAP5 diluted in 
100 μl of physiological saline, or 4 μg of PENK diluted in 100 μl of physio-
logical saline. The mice were monitored for survival for 7 days (168 hours).
Quantification of lung histology. Quantification of mononuclear cells and 
alveolar space in H&E stained lung sections was performed in 10 random 
per animal using the public software ImageJ (http://rsb.info.nih.gov/ij/). 
Mononuclear cells were quantified using particle counts of nuclei that were 
set with appropriate criteria for a specific threshold of staining intensity 
as well as corresponding sizes of the nuclei. Nuclei of area less than 500 
pixel2 were analyzed to identify infiltrating inflammatory cells from lung 
parenchyma and resident nonparenchymal cells. Alveolar space was cal-
culated using a threshold function of ImageJ, excluding edges of images, 
which calculated the area of only multicellular structures enclosing central 
whitespace at ×10 magnification. Data are presented as percentage differ-
ences of each parameter compared to saline-treated LPS mice as a baseline.
SUPPLEMENTARY MATERIAL
Figure S1. Flow cytometry of BM-MSCs.
Figure S2. IL-10 assay time course and effect of proteinase K on the 
activity of BM-MSC-CM.
Figure S3. Interferon-γ potency assay.
Figure S4. Liquid chromatography of BM-MSC-CM.
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